학술논문
VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors (1275)
Document Type
Abstract
Author
Source
In Gynecologic Oncology September 2023 176 Supplement 1:S173-S173
Subject
Language
ISSN
0090-8258